<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602160</url>
  </required_header>
  <id_info>
    <org_study_id>R01AT001495-01A1</org_study_id>
    <secondary_id>R01AT001495-01A1</secondary_id>
    <nct_id>NCT00602160</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Chinese Herbal Medicine on Food Allergy</brief_title>
  <acronym>FAHF-2</acronym>
  <official_title>Investigation of the Efficacy of the Food Allergy Herbal Formula (FAHF-2TM) in Patients With Food Allergy - Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Li, Xiu-Min, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Li, Xiu-Min, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increasing prevalence of allergic diseases in westernized countries poses a significant&#xD;
      health problem and a tremendous burden on quality of life and healthcare expenditure. Food&#xD;
      allergy affects as many as 6% of young children and 3% to 4% of adults. While the majority of&#xD;
      children outgrow their allergy to milk, egg, wheat and soy, allergies to peanut, tree nuts,&#xD;
      fish and shellfish are often life-long. Currently, there are no treatments that can cure or&#xD;
      provide long-term remission from food allergy. Based on our preliminary studies, we&#xD;
      hypothesize that our investigational botanical drug, FAHF-2TM, will be a safe and effective&#xD;
      herbal therapy for food allergy. We are enrolling those age 12-45 yrs old with allergies to&#xD;
      peanut, tree nuts, sesame, fish, and/or shellfish.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To address our hypothesis, we propose the following aims:&#xD;
&#xD;
      Aim #1: To investigate the efficacy of FAHF-2TM for food allergy (in addition to current food&#xD;
      allergen avoidance).&#xD;
&#xD;
      Aim #2: To characterize the immunomodulatory effects of FAHF-2TM on food allergic patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of FAHF-2</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>lab studies</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 different dosages</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FAHF-2 (TM)</intervention_name>
    <description>We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.&#xD;
Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects ages 12 through 45 years of age and otherwise in good health&#xD;
             as determined by medical history and physical examination&#xD;
&#xD;
          -  History of allergy to peanut, tree nut, sesame, fish or shellfish as documented by a&#xD;
             positive skin test and/or food allergen-specific IgE level.&#xD;
&#xD;
          -  The subject agrees to participate in the study or the subject's parent or legal&#xD;
             guardian is willing and able to give written informed consent, and the pediatric&#xD;
             subject gives assent for participation in the study.&#xD;
&#xD;
          -  Positive double-blind placebo controlled food challenge to peanut, tree nuts, sesame,&#xD;
             fish, or shellfish.&#xD;
&#xD;
          -  Females of childbearing potential must be inactive sexually or take effective birth&#xD;
             control measures, as deemed appropriate by the investigator, for the duration of the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of life-threatening anaphylaxis to peanut, tree nut, sesame, fish or shellfish&#xD;
             (involving hypotension or requiring mechanical ventilation)&#xD;
&#xD;
          -  Allergy to corn&#xD;
&#xD;
          -  Acute febrile illness (such as cold, flu, etc.) within one week before administration&#xD;
             of study drug&#xD;
&#xD;
          -  Any history of systemic disease that in the investigator's opinion would preclude the&#xD;
             subject from participating in this study, e.g. autoimmune disease, neoplasms, HIV or&#xD;
             hepatitis virus infection&#xD;
&#xD;
          -  Allergic gastrointestinal disease (e.g. allergic eosinophilic&#xD;
             esophagitis/gastroenteritis&#xD;
&#xD;
          -  Abnormal hepatic function (ALT/AST and bilirubin &gt;1.25 x upper limit of normal)&#xD;
&#xD;
          -  Abnormal bone marrow function (WBC &lt;4 x 103/mm3; platelets &lt;100 x 103/mm3; hgb &lt;11&#xD;
             g/dl)&#xD;
&#xD;
          -  Abnormal renal function (BUN and creatinine &gt;1.25 x upper limit of normal)&#xD;
&#xD;
          -  Clinically significant abnormal electrocardiogram&#xD;
&#xD;
          -  Current uncontrolled moderate to severe asthma as defined by:&#xD;
&#xD;
               1. FEV1 value &lt;80% predicted or any clinical features of moderate or severe&#xD;
                  persistent asthma baseline severity (as defined by the 2007 NHLBI Guidelines) and&#xD;
                  greater than high daily doses of inhaled corticosteroids (as defined for children&#xD;
                  and adults using dosing tables from the 2007 NHLBI Guidelines).&#xD;
&#xD;
               2. Use of steroid medications in the following manners: history of daily oral&#xD;
                  steroid dosing for &gt;1 month during the past year, or burst or steroid course in&#xD;
                  the past 6 months, or &gt;1 burst oral steroid course in the past year.&#xD;
&#xD;
               3. Asthma requiring &gt;1 hospitalization in the past year for asthma or &gt;1 ED visit in&#xD;
                  the past 6 months for asthma.&#xD;
&#xD;
          -  Participation in another experimental therapy study within 30 days of this study&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Currently taking antidepressant medication&#xD;
&#xD;
          -  Pregnant or lactating female subjects. Females of childbearing potential will need a&#xD;
             negative serum pregnancy test at screening to be considered for this study&#xD;
&#xD;
          -  Use of omalizumab&#xD;
&#xD;
          -  Use of beta blockers, ACE inhibitors, ARB, or calcium channel blockers, or history of&#xD;
             ischemic heart disease&#xD;
&#xD;
          -  Inability to discontinue use of antihistamines for skin testing or oral food&#xD;
             challenges&#xD;
&#xD;
          -  Inability to take the tablets&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiu-Min Li</last_name>
    <role>Study Director</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JingJing Mei</last_name>
    <phone>212-241-6577</phone>
    <email>jingjing.mei@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon M Hamlin</last_name>
    <phone>212-241-1755</phone>
    <email>sharon.hamlin@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>June Staw</last_name>
      <email>JAStraw@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christie Lynn</last_name>
      <email>ChristieLynn@uams.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stacie Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julie Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>November 3, 2010</last_update_submitted>
  <last_update_submitted_qc>November 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Xiu-Min Li, M.D.</name_title>
    <organization>Mount Sinai School of Medicine</organization>
  </responsible_party>
  <keyword>Food allergy</keyword>
  <keyword>Chinese Herbs</keyword>
  <keyword>Investigational new drug</keyword>
  <keyword>Herbs</keyword>
  <keyword>Therapeutic medicine</keyword>
  <keyword>Traditional Chinese medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

